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Recently, we identiﬁed and cloned a membrane-based estrogen receptor (ER), ER-a36, which is tran-
scribed from a previously unidentiﬁed promoter in the ﬁrst intron of the original ER-a gene. We
cloned the 50 ﬂanking region of ER-a36 and found the cloned DNA sequence possessed strong pro-
moter activity. A single transcription initiation site was mapped and a number of putative regula-
tory elements for various transcription factors such as the Wilms’ tumor suppressor, WT1 and
estrogen receptor (ER) were identiﬁed in this region. Transient co-transfection experiments further
demonstrated that ER-a suppresses ER-a36 promoter activity in an estrogen-independent manner,
which can be released by ER-a36 itself.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Diverse functions of estrogens are mediated by estrogen recep-
tors: ER-a and ER-b. Both ER-a and ER-b function as ligand-depen-
dent transcription factors and consist of an N-terminal activation
function 1 (AF1) domain, a DNA-binding domain, and a C-terminal
ligand-binding domain that harbors an activation function 2 (AF2)
domain [1–4]. The liganded ERs readily form homodimers or het-
erodimers that interact with the palindromic estrogen response-
element (ERE) in the promoter regions of estrogen responsive
genes and stimulate gene transcription [1–4]. Alternatively, ER-a
may act indirectly by tethering to other transcription factors, such
as Sp1 and AP1 to modulate activities of these transcription factors,
which in turn regulates downstream gene expression [1–5].
For the past 30 years, accumulating evidence demonstrates a ra-
pid (within seconds or minutes) estrogen action that cannot be ex-
plained by the genomic signaling pathway that usually requires
hours to reach maximal gene activation [6–11]. This pathway is
also called the ‘‘non-classical”, ‘‘extra-nuclear”, ‘‘non-genomic” or
‘‘membrane-associated” estrogen signaling pathway [8,9]. How-
ever, the identity of the membrane-based estrogen receptor that
mediates these rapid estrogen effects has not been well
established.
Recently, we identiﬁed and cloned a variant of ER-a with a
molecular weight of 36 kDa that is transcribed from a previouslyon behalf of the Federation of Euro
Microbiology, University of
nter, Omaha, NE 68198, USA.unidentiﬁed promoter located in the ﬁrst intron of the original
ER-a (ER-a66) gene [12,13]. This novel isoform of ER-a, ER-a36
lacks both transcriptional activation domains of ER-a (AF1 and
AF2), but retains the DNA-binding domain and partial dimerization
and ligand- binding domains. ER-a36 is predominantly expressed
on the cell surface and mediates the membrane-initiated estrogen
signaling [13], indicating that ER-a36 is a membrane-based estro-
gen receptor and a novel player in mitogenic estrogen signaling.
Our recent study also revealed that ERa36 is not only expressed
in ER-positive breast cancer but also expressed in ER-negative
breast cancer that lacks expression of ER-a66 [14], further indicat-
ing that ER-a36 is subjected to a totally different transcriptional
regulation from the original ER-a. As an important mediator of
estrogen signaling, ER-a36 must be regulated dynamically and
strictly to maintain a normal estrogen signaling. Dysregulation of
its expression may be involved in development of a number of hu-
man diseases including breast cancer.
In order to elucidate the molecular mechanisms underlying reg-
ulation of this biologically important gene, we isolated and cloned
the 50-ﬂanking region of ER-a36, and characterized the general fea-
tures of this region.2. Materials and methods
2.1. Cell culture and luciferase reporter assay
MCF10A cells were obtained from Karmanos Cancer Institute,
Detroit, MI. Human embryonic kidney (HEK) 293 cells, human
breast cancer cells, MCF7, T47D, MDA-MB-231, MDA-MB-436,pean Biochemical Societies.
Table 2
Oligonucleotides used in the 50 RACE PCR.
AP1 (S) 50 CCATCCTAATACGACTCACTATAGGGC 30
AP2 (S) 50 ACTCACTATAGGGCTCGAGCGGC 30
GSP1 (AS) 50 CCTTGCAGCCCTCACAGGACCAGACTCC 30
GSP2 (AS) 50 TCTCCTTGGCAGATTCCATAGCC 30
(S): sense; (AS): anti-sense. API (S), GSP1 (AS) and AP2 (S), GSP2 (AS) were two sets
of primers used for the 50 RACE.
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American Type Culture Collection (ATCC). All cells were main-
tained at 37 C in a 5% CO2 atmosphere in appropriate tissue cul-
ture medium.
Expression vectors, pCR3.1-ER-a66 and pCR3.1-ER-a46 were
obtained from Dr. Zafar Nawaz at the University of Miami Sylvester
Comprehensive Cancer. The expression vectors pCR3.1-ER-a36 was
constructed as described before [12]. Amounts of the expression
vectors used in each transfection assay were normalized by the
empty expression vector pCR3.1. The luciferase assays were per-
formed using the Dual Luciferase Assay kit from Promega accord-
ing to the manufacturer’s recommendation.
2.2. Molecular cloning of the 50-ﬂanking region of ER-a36
According to computer analysis, ER-a36 mRNA is initiated from
a promoter located in the ﬁrst intron of ER-a genomic DNA. Using a
human placenta genomic DNA library (Clontech Laboratories Inc.)
as a template, the 50-ﬂanking region of ER-a36 was ampliﬁed by
a genomic PCR kit (Clontech Laboratories Inc.), using a primer set
containing XhoI or HindIII restriction sites at the ends, respec-
tively: forward primer 50-CCCTCGAGGGTACCCGCGCCCGC-30 and
reverse primer 50-CCAAGCTTAAAAATTCGTGAACACGAAGG-30. The
ampliﬁed 751 bp DNA product was cloned into a TA cloning
pCR2.1 vector (Invitrogen) and veriﬁed by DNA sequencing on both
strands. The putative transcription factor binding sites in the 50
ﬂanking region of ER-a36 gene were analyzed using the AliBaba
2.1 promoter analysis software.
2.3. Construction of the 50 deletion mutants of ER-a36 promoter
The DNA fragment generated by genomic PCR was cloned up-
stream of a luciferase reporter gene in a promoter-less pGL2-basic
luciferase reporter vector (Promega Co.). The resulted plasmid was
named as pGL2-ER36. The 50-deletion mutants of ER-a36 promoter
were produced by PCR method from the pGL2-ER36 plasmid. Prim-
ers were designed with HindIII and XhoI sites at the ends of the
products (Table 1). The PCR products were puriﬁed and cloned into
the HindIII and XhoI sites upstream of a luciferase reporter gene in
the pGL2-basic vector (Promega Co.). All plasmids were then veri-
ﬁed by restriction enzyme digestion and DNA sequencing. The se-
ven deletion mutants were named pGL2-ER36 [1–7].
2.4. Rapid ampliﬁcation of 50 cDNA end (50 RACE)
The transcription initiation site in the 50 ﬂanking sequence of
ER-a36 was identiﬁed with the 50 RACE method. Human placenta
‘‘marathon-ready” cDNA from Clontech Inc. was used to perform
50 RACE according to the manufacturer’s instruction. An ER-a36
gene-speciﬁc primer 1 (GSP1) was designed (Table 2) for the
touch-down PCR, and paired with an adaptor primer 1 (AP1) pro-
vided by the kit. Secondary PCR was performed with the gene spe-Table 1
Primers used to generate 50 deletion constructs of human ER-a36 promoter.
50P36-1 S 50-CCCTCGAGCCGCGGGACGCGCGACCCGA-30
50P36-2 S 50-CCCTCGAGCCCGGGGGTTCTGCGTGCAGC-30
50P36-3 S 50-CCCTCGAGTACTCTCCACCCACTTACCGTC-30
50P36-4 S 50-CCCTCGAGGCAAATAAACACGGGGCGCTTTG-30
50P36-5 S 50-CCCTCGAGGAAGGTCTCGCTCTTGGCATTT-30
50P36-6 S 50-CCCTCGAGTTTTATTTATCCTTTTAATGTTTTTGTTTAAT-30
50P36-7 S 50-CCCTCGAGCCTTTTAATGTTTTTGTTTAATGTGCTCCCC-30
30P36-1 AS 50-CCAAGCTTGTGCTTCCATATGGCTTGTTTTAAAC-30
All the 50 deletion mutants were generated with the common anti-sense primer
(AS) but different sense primers (S). Restriction enzyme sites incorporated for easy
cloning were underlined.ciﬁc primer 2 (GSP2) and nested primer AP2 from the kit. The PCR
products from the 50 RACE were cloned into the TA cloning pCR2.1
vector and examined by DNA sequencing.
2.5. RNA extraction, RT-PCR and semi-quantitative analysis
Total RNA was isolated with Trizol (Invitrogen) from cells
according to the manufacture’s instructions. RNA integrity was
examined by gel-electrophoresis with 1% formaldehyde gel.
500 ng total RNA was reverse transcribed with Protoscript II RT-
PCR kit (New England BioLabs). PCR was performed in a ﬁnal vol-
ume of 50 ll containing 2 ll RT transcript, 0.2 lM of each primer,
25 ll Taq 2XMaster Mix. The following primers were used: ER-a66
forward primer: 50-CACTCAACAGCGTGTCTCCGA-30; ER-a66 re-
verse primer: 50-CCAATCTTTCTCTGCCACCCTG-30; ER-a36 forward
primer 50-CACTCAACAGCGTGTCTCCGA-30; ER-a36 reverse primer
50-CCAATCTTTCTCTGCCACCCTG-30; b-actin forward primer 50-
TGACGGGGTCACCCACACTGTGCCCATCTA-30; b-actin reverse pri-
mer 50-CTAGAAGCATTTGCGGTGGACGATGGAGGG-30. Samples
were ampliﬁed: ER-a36 35 cycles, ER-a66 35 cycles and b-actin,
25 cycles. PCR products (20 ll) were electrophoresed on 1.2% aga-
rose gel and visualized under ultraviolet light after ethidium bro-
mide staining. Fragment sizes were 286 bp for ER-a36, 200 bp for
ER-a66 and 661 bp for b-actin. The band densities of ER-a36,
ER-a66 and b-actin were determined with a video-densitometry
system (Molecular Imager ChemiDoc XRS System, Bio-Rad). Subse-
quently, the ER-a36:b-actin ratio and ER-a66:b-actin ratio (b-actin
mRNAs were detected in the same RT sample) were calculated
with the Quantity One software.
2.6. Statistical analysis
Data were summarized as the mean ± standard error (S.E.) using
GraphPad InStat software program. The student t-test was also
used, and the signiﬁcance was accepted for P-values of less than
0.05.
3. Results
3.1. Genomic cloning and sequence analysis of the 50 ﬂanking region of
ER-a36 gene
ER-a36 is a membrane-based estrogen receptor that mediates
non-genomic estrogen signaling and stimulates cell growth [13].
ER-a36 is expressed in specimens from ER-negative breast cancer
patients that lack expression of ER-a66 [14], suggesting that its
expression is regulated independently and differently from the
ER-a66 gene. However, the molecular mechanisms by which
ER-a36 gene transcription is regulated are unknown. We decided
to clone the promoter region of ER-a36 and to study its transcrip-
tional regulation. To this aim, we designed primers corresponding
to the 50 ﬂanking sequence upstream of the ER-a36 cDNA accord-
ing to the published genomic sequence of the ER-a66 gene (ESR1,
Gene bank AY425004). A genomic PCR assay was performed using
human genomic DNA from placenta. An expected 751 bp PCR prod-
uct was cloned into a TA cloning vector (pCR2.1), and completely
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50 ﬂanking region contains a high G + C content, a non-canonical
TATA box, but lacks the CCAAT box. A number of SP1 sites and
AP1 sites were identiﬁed in the 50 ﬂanking region of ER-a36
(Fig. 1). The region also contains putative binding sites for the fol-
lowing transcription factors: AhR (aryl hydrocarbon receptor), Erg-
1 (ETS-related gene 1), NF-jB (nuclear factor kappa B), WT1 (the
Wilms’ tumor suppressor), PU.1, GATA-1, Elk-1 and GR (glucocorti-
coid receptor). This region lacks consensus palindromic ERE site
(50-GGTCAnnnTGACC-30); however, it contains an imperfect ERE
half site (50-AGTCA-30, located at 369 to 365, relative to the
transcription initiation site) that is overlapped with an AP-1 bind-
ing site (Fig. 1).
3.2. Transcription initiation site of ER-a36 gene and promoter activity
To map the transcription start site of ER-a36, we used human
placenta ‘‘marathon-ready” cDNA as templates to perform 50 RACE
assay and cloned PCR products into the TA cloning pCR2.1 vector.
The DNA clones were sequenced from both directions. We found
all DNA clones contained sequences matched exactly to the se-
quences of the ER-a66 genomic DNA. Two clones contained identi-
cal sequences corresponding to the 50 end of the ER-a36 cDNA.
After comparing these two DNA sequences with the 50 ﬂanking se-
quence of ER-a36 gene, we mapped the ﬁrst nucleotide of the tran-
scription initiation at the nucleotide A (+1) 238 bp upstream of the
translation initiation site (Fig. 1).
To determine that the 50 ﬂanking region of ER-a36 gene con-
tains promoter activity, we placed the 751 bp DNA fragment inFig. 1. Nucleotide sequence of the 50 ﬂanking region of ER-a36 gene and putative regulat
half site, are underlined. The putative TATA box is shown as an open box. Curved arrow
the left are relative to the transcription start site of ER-a36.the front of the ﬁreﬂy luciferase gene of the pGL2-basic vector to
generate the plasmid pGL2-ER36. The plasmid pGL2-ER36 was
transiently transfected into HEK293 cells and the promoter activity
was assessed by measuring luciferase activity in the transfected
HEK293 cells. As shown in Fig. 2, pGL2-ER36 exhibited about 14-
fold higher promoter activity compared to the empty vector that
produced barely detectable luciferase activity. The basal activity
of the ER-a36 promoter is about half of that of the SV-40 pro-
moter/enhancer activity in HEK293 cells (Fig. 2).
3.3. Deletion analysis of the ER-a36 promoter
To further characterize the 50 ﬂanking region of the ER-a36
gene, we constructed a set of seven reporter vectors, containing
successive 50 deletion of the ER-a36 promoter (Fig. 3). These dele-
tion mutants were then transfected into three cell lines: HEK293,
ER-negative breast cancer MDA-MB-231 cells and ER-positive
breast cancer MCF7 cells, and the luciferase activities of these con-
structs were then measured. In HEK293 cells, a signiﬁcant increase
of promoter activity was observed with the removal of 50 sequence
up to nucleotide 584 bp (relative to the transcription initiation
site), indicating the presence of negative regulatory element(s) in
the region from736 bp to584 bp in HEK 293 cells. Further trun-
cation to 513 bp returned the promoter activity to the full-length
promoter activity, suggesting the presence of positive regulatory
element(s) in the region 584 bp to 513 bp. In ER-positive breast
cancer MCF7 cells, however, a decrease of promoter activity was
observed in the deletion of the DNA sequence 736 bp to
675 bp, indicating the presence of enhancer element(s) in thisory elements. Potential binding sites of AP-1, Sp1, AhR, NF-jB, and WT1, and an ERE
indicates the transcription start site mapped by the 50 RACE. The numbers shown at
Fig. 2. The promoter activity in the 50 ﬂanking region of ER-a36. The pGL2-ER36,
the promoter-less pGL2 plasmid and the positive pSV-Luc were transfected into
HEK293 cells, respectively. The luciferase reporter activity was measured. Relative
luciferase activities are shown with the luciferase activity in pGL2 empty vector
transfected cells was set as 1. Columns: mean of more than three independent
experiments; bars, S.E. *P < 0.05 vs. the promoter-less pGL2 plasmid transfected
cells.
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the remaining deletion constructs. In ER-negative breast cancer
MDA-MB-231 cells, there are no signiﬁcant changes of the pro-
moter activities of all deletion mutants. In three cell lines, the pro-
moter activity was dramatically reduced after the putative TATA
box was deleted, indicating its essential role in the optimal pro-
moter activity of ER-a36 gene. Taken together, these results dem-
onstrated that both negative and positive regulatory regions
controlled the basal promoter activity of ER-a36 gene depending
on cell context.
3.4. Suppression of the ER-a36 promoter activity by ER-a66
Since there is one imperfect ERE half site (369 bp to 365 bp)
in the ER-a36 promoter, we decided to test whether ER-a66 regu-
lates ER-a36 promoter activity using HEK293 cells that express no
detectable level of endogenous ER-a. The results from transient co-
transfection indicated that co-transfection of ER-a66 expression
vector with pGL-ER36 reporter plasmid resulted in about 2-fold
repression of ER-a36 promoter activity (Fig. 4) and this suppres-
sion was not changed in the presence of 17b-estrodial (data not
shown). However, the combination of ER-a66 and ER-a36 or ER-
a46, another ER-a variant that lacks the AF-1 domain [23] released
the suppression activity of ER-a66 while co-transfection with ER-
a36 or ER-a46 expression vector alone has no effect on ER-a36promoter activity (Fig. 4). These results suggested that ER-a66 sup-
presses ER-a36 promoter activity in an estrogen-independent
manner presumably through the AF1 domain, which can be re-
leased by co-expression of either ER-a46 or ER-a36 itself both of
which lack the AF1 domain.
We also examined expression patterns of ER-a66 and 36 in
established breast cancer cell lines with RT-PCR analysis. ER-a36
was not expressed in normal mammary epithelial cells MCF10A,
weakly expressed in ER-positive breast cancer cells such as MCF7
and T47D both of which express high levels of ER-a66. ER-a36
was highly expressed in ER-negative breast cancer cells such as
MDA-MB-231 cells that lack ER-a66 expression (Fig. 5). However,
the ER-negative breast cancer MDA-MB-436 cells express low lev-
els of ER-a36. ER-a36 was also highly expressed in the ER-positive
breast cancer cells H3396 that have high levels of ER-a46 expres-
sion (Fig. 5, data not shown). ER-a36 was also detected in lung can-
cer H226 cells that lack ER-a66 expression (Fig. 5). The different
expression patterns of ER-a66 and 36 in these cancer cells further
indicated that ER-a36 is transcriptionally regulated differently
from ER-a66.4. Discussion
In this study, we have isolated and cloned a DNA fragment con-
taining the promoter region of ER-a36 gene that is located in the
ﬁrst intron of the human ER-a66 gene. Functional analysis demon-
strated that this DNA sequence exhibited strong promoter activity,
indicating that this region contains ER-a36 promoter. We also fur-
ther determined a single transcription start site at the nucleotide A
238 bp upstream of the translation initiation site. Sequence analy-
sis revealed that the ER-a36 promoter region contains a high G + C
content, a non-canonical TATA box and multiple Sp1 binding sites.
Deletion of these Sp1 sites and the non-canonical TATA box re-
sulted in signiﬁcantly decreased promoter activity, suggesting
these DNA sequences are critical for the optimum ER-a36 pro-
moter activity.
To further analyze ER-a36 promoter, we constructed a series of
50 truncations of the ER-a36 promoter region and tested promoter
activities of these truncated promoters with transient transfection
in three cell lines: HEK293 cells, ER-positive breast cancer MCF7
cells and ER-negative breast cancer MDA-MB-231 cells. HEK293
cells express undetectable levels of both ER-a66 and 36; MCF7
cells weakly express ER-a36 but highly express ER-a66 while ER-
negative breast cancer MDA-MB-231 cells only express ER-a36.
These cell lines presumably provide different genetic background
to test ER-a36 promoter activity. In HEK293 cells, the highest tran-
scriptional activity was observed for the promoter deletion 2 (re-
moval of DNA sequence from 675 bp to 584 bp), suggesting
existence of negative element(s) in this region. We observed a Wil-
ms’ tumor suppressor WT1 binding site within this region. In pre-
liminary study, we found that WT1 expression inhibited ER-a36
promoter activity through this binding site (unpublished data),
suggesting that deletion of the WT1 binding site may release
WT1 suppression activity in HEK293 cells that highly express the
transcription suppressor WT1. It is worth noting that loss of WT1
expression was implicated in development of breast cancer [15].
Aberrant methylation of WT1 promoter was also found in breast
cancer [16,17]. Our laboratory previously demonstrated that
over-expression of recombinant WT1 in MDA-MB-231 cells inhib-
its malignant growth of breast cancer cells [18]. Thus, the ﬁnding
here that deletion of the WT1 binding site increased ER-a36 pro-
moter activity suggested that WT1 is involved in negative regula-
tion of ER-a36 expression and aberrant WT1 expression may
lead to the increased ER-a36 expression observed in breast cancer.
We also noticed that several deletion mutants of the ER-a36 ﬂank-
Fig. 3. Promoter activities of serial deletion mutants of ER-a36 promoter in HEK293, MDA-MB-231, MCF7 cells. The schematic diagram of the full-length and 50 serial
truncation constructs of ER-a36 promoter (left panel) and their corresponding luciferase activities in different cell types are shown. Positions of the deletions are indicated
and the curved arrow indicates the transcription start site. P0: the full-length promoter in the pGL2-ER36 plasmid; P1–7: seven deletion mutants of ER-a36 promoter, pGL2-
ER36 (1–7). Relative luciferase activities are shown with the luciferase activities in pGL2-ER36 vector transfected cells were set as 1. Columns: mean of more than three
independent experiments; bars, S.E. *P < 0.01 vs. the full-length promoter, the pGL2-ER36 plasmid transfected MCF7 cells; NP < 0.01 vs. the pGL2-ER36 plasmid transfected
MDA-MB-231 cells; jP < 0.01 vs. the pGL2-ER36 plasmid transfected HEK293 cells.
Fig. 4. Regulation of ER-a36 promoter activity by ER-a isoforms. HEK293 cells were transiently co-transfected with the pGL2-ER36 luciferase reporter plasmid alone or with
the expression vectors of ER-a66, ER-a46 or ER-a36, respectively, or in different combinations. Relative luciferase activities are shown with the luciferase activity in pGL2-
ER36 vector transfected cells was set as 1. Columns:mean of more than three independent experiments; bars, S.E. *P < 0.05 vs. the empty vector transfected cells. **P < 0.05 vs.
the pCR3.1-ER-a66 transfected cells.
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pared to MCF7 and MDA-MB-231 cells although HEK293 cells ex-
press undetectable levels of ER-a36 expression [13], suggesting
that other mechanisms such as DNA methylation may occur in
the G + C rich promoter region of ER-a36 and contribute to the reg-
ulation of ER-a36 expression.
In MCF7 cells, the full-length promoter exhibited highest pro-
moter activity; deletion of the DNA sequence from 736 bp to
675 bp that harbors several Sp1 binding sites dramatically re-
duced the promoter activity, suggesting these Sp1 sites act as pos-itively regulatory elements. In MDA-MB-231 cells, most deletion
mutants display similar promoter activity.
It is well established that ER-a binds to the palindromic estro-
gen response-element (ERE) in the target genes and regulates gene
transcription [4]. It was also reported that ER-a regulates promot-
ers containing ERE half sites [19]. Other studies suggested that ER-
a binds to a single ERE half-site closely located with Sp1 binding
sites in the presence of Sp1 binding in the promoters of certain
estrogen regulated genes such as hsp27 [20], TGF-alpha [21] and
PR [22]. ER-a36 promoter contains an imperfect ERE half site in
Fig. 5. Expression of ER-a66 and 36 in different cancer cells. Total RNA was prepared from cultured cancer cells. RT-PCR was used to examine mRNA levels of ER-a66 and ER-
a36 in cells. Housekeeping gene b-actin was used as an internal control. RT-PCR products were electrophoresed on a 1.2% agarose gel and visualizer by staining with ethidium
bromide (A). The levels of mRNA expression of ER-a36, ER-a66 and b-actin were determined with a video-densitometry system and the ER-a36:b–actin ratio and ER-a66:b-
actin ratio was calculated with the Quantity One software (Bio-Rad Laboratories). The band densities relative to the density of b–actin band were shown (B).
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this study, we found that expression of the original 66-kDa ER-a
(ER-a66) suppressed ER-a36 promoter activity in an estrogen-
independent manner, presumably through binding to the ERE half
site. Flouriot et al. [23] cloned a 46-kDa isoform of ER-a and dem-
onstrated that the 46-kDa isoform lacking the ﬁrst 173 amino acids
(A/B or AF-1 domain) is derived from alternative splicing of the ER-
a gene by skipping exon 1. This isoform of ER-a was named as ER-
a46 and the original one as ER-a66 [23]. ER-a46 forms homodi-
mers and heterodimers with ER-a66 [23]. Furthermore, the ER-
a46/66 heterodimers form preferentially over the ER-a66 homodi-
mers and ER-a46 acts competitively to inhibit transcription activ-
ity mediated by the AF-1 domain of ER-a66 but without effect on
an AF-2-dependent transactivation [23]. Here, we found that co-
expression ER-a46 or ER-a36 itself released suppression activity
mediated by ER-a66. The molecular mechanism underlying this re-
lease of suppression is currently unknown. The competitive bind-
ing to the ERE half site by these ER-a isoforms, or heterodimer
formation between ER-a66 and ER-a36 or ER-a46 to block theAF1 function of ER-a66, may explain this phenomenon. It was re-
ported that BRCA1 mediates the ligand-independent transcrip-
tional repression activity of the ER-a66 through its AF-1 domain
[24]. Thus, it may be possible that BRCA1 is involved in transcrip-
tional suppression activity mediated by ER-a66 and BRCA1 muta-
tions may lead to upregulation of ER-a36 expression and its
activity in BRCA1-related breast cancer.
Recently, we found that singling pathways mediated by EGFR,
HER2 and GPR30 regulates ER-a36 expression at both transcrip-
tional and post-transcriptional levels (Kang and Wang, unpub-
lished observations), suggesting as an important player in
estrogen signaling, ER-a36 is regulated strictly at both mRNA
and protein levels. This may also provide an explanation for the ob-
served inconsistence of ER-a36 expression in MDA-MB-436 cells;
low mRNA levels but high protein levels observed before [13]. Fur-
ther study of the molecular mechanisms by which ER-a36 is regu-
lated at the transcription and post-transcription levels will provide
novel and important insights for the biological function of ER-a36
in many physiological and pathological processes.
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